Roche Shelves Phase III Huntington's Candidate Tominersen
Follows Independent Committee Data Review
Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.
